Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Receivables: 2023-2024

Historic Receivables for Krystal Biotech (KRYS) over the last 2 years, with Dec 2024 value amounting to $104.7 million.

  • Krystal Biotech's Receivables rose 33.23% to $129.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $449.1 million, marking a year-over-year increase of 29.31%. This contributed to the annual value of $104.7 million for FY2024, which is 149.16% up from last year.
  • According to the latest figures from FY2024, Krystal Biotech's Receivables is $104.7 million, which was up 149.16% from $42.0 million recorded in FY2023.
  • In the past 5 years, Krystal Biotech's Receivables ranged from a high of $104.7 million in FY2024 and a low of $42.0 million during FY2023.
  • Moreover, its 2-year median value for Receivables was $73.4 million (2023), whereas its average is $73.4 million.
  • Data for Krystal Biotech's Receivables shows a peak YoY spiked of 149.16% (in 2024) over the last 5 years.
  • Krystal Biotech's Receivables (Yearly) stood at $42.0 million in 2023, then skyrocketed by 149.16% to $104.7 million in 2024.